Mycobacterium malmoense in the north-east of England.
We report a 6 year experience (1979-1984) of isolating Mycobacterium malmoense in the north-east of England. Eleven subjects were involved of whom 10 had active infection--9 pulmonary, one cervical adenitis. The 11 new isolates represent 0.7% of all new mycobacterial isolates during this period and 10% of new non-tuberculous isolates. In all but 2 cases there was pre-existing pulmonary disease and/or a recognised predisposing factor to mycobacterial infection. The organisms were generally insensitive to isoniazid but sensitive to both rifampicin and ethionamide. The results of chemotherapy are described.
D000328:Adult; D004359:Drug Therapy, Combination; D004739:England; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000188:drug therapy / Q000382:microbiology*; D008199:Lymphadenitis / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D009161:Mycobacterium / Q000302:isolation & purification*; D009164:Mycobacterium Infections / Q000188:drug therapy / Q000382:microbiology*; D012293:Rifampin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology
D005000:Ethionamide; D012293:Rifampin